Abstract
Umbilical cord blood (UCB) has become an alternative source of hematopoietic progenitors (HSC) for transplantation. Although most CB transplants have been performed in children, unrelated donor-cord blood transplants in adults have been growing steadily in recent years. HSC content of CB units influence significantly the transplantation outcome, as shown by many clinical studies. UCB banks are fundamental to support this increasing clinical activity and one of their main goals must be to store good quality units. Strategies for increasing HSC content of UCB units are reviewed and also its influence on transplantation outcome. Our bank selected the UCB units for cryopreservation on the basis of their total nucleated cells (TNC) and CD34+ cells content. We also reviewed the results of our UCB bank program.
Keywords: Total nucleated cells, colony-forming progenitor cells, megakaryocyte, transplantation, CD34 cell content
Current Stem Cell Research & Therapy
Title: Banking Strategies for Improving the Hematopoietic Stem Cell Content of Umbilical Cord Blood Units for Transplantation
Volume: 3 Issue: 2
Author(s): Pilar Solves, Vicente Mirabet, Alfredo Perales, Francisco Carbonell-Uberos and Roberto Roig
Affiliation:
Keywords: Total nucleated cells, colony-forming progenitor cells, megakaryocyte, transplantation, CD34 cell content
Abstract: Umbilical cord blood (UCB) has become an alternative source of hematopoietic progenitors (HSC) for transplantation. Although most CB transplants have been performed in children, unrelated donor-cord blood transplants in adults have been growing steadily in recent years. HSC content of CB units influence significantly the transplantation outcome, as shown by many clinical studies. UCB banks are fundamental to support this increasing clinical activity and one of their main goals must be to store good quality units. Strategies for increasing HSC content of UCB units are reviewed and also its influence on transplantation outcome. Our bank selected the UCB units for cryopreservation on the basis of their total nucleated cells (TNC) and CD34+ cells content. We also reviewed the results of our UCB bank program.
Export Options
About this article
Cite this article as:
Solves Pilar, Mirabet Vicente, Perales Alfredo, Carbonell-Uberos Francisco and Roig Roberto, Banking Strategies for Improving the Hematopoietic Stem Cell Content of Umbilical Cord Blood Units for Transplantation, Current Stem Cell Research & Therapy 2008; 3 (2) . https://dx.doi.org/10.2174/157488808784223096
DOI https://dx.doi.org/10.2174/157488808784223096 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biofunctional Peptides from Milk Proteins: Mineral Binding and Cytomodulatory Effects
Current Pharmaceutical Design The Epithelial-Mesenchymal Transition and Cancer Stem Cells: Functional and Mechanistic Links
Current Pharmaceutical Design Selective Binding BAFF/APRIL by the In and Outside Conservative Region of BCMA
Protein & Peptide Letters Promoters and Control Elements: Designing Expression Cassettes for Gene Therapy
Current Gene Therapy Nitrogen-Containing Heterocycles as Anticancer Agents: An Overview
Anti-Cancer Agents in Medicinal Chemistry NF-κB Blockers Gifted by Mother Nature: Prospectives in Cancer Cell Chemosensitization
Current Pharmaceutical Design Isoform Characterisation, Heterologous Expression and Functional Analysis of Two Lectins from Vatairea macrocarpa
Protein & Peptide Letters Nitrosative Stress as a Mediator of Apoptosis: Implications for Cancer Therapy
Current Pharmaceutical Design Transport of Nucleoside Analogs Across the Plasma Membrane: A Clue to Understanding Drug-Induced Cytotoxicity
Current Drug Metabolism Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications
Current Pharmaceutical Design Synthesis of Cis-Fused Pyran Indolocarbazole Derivatives that Inhibit FLT3 Kinase and the DNA Damage Kinase, Checkpoint Kinase 1
Anti-Cancer Agents in Medicinal Chemistry Anti-Cancer Therapeutic Approaches Based on Intracellular and Extracellular Heat Shock Proteins
Current Medicinal Chemistry Cytotoxic T Cell Reponses Against Immunoglobulin in Malignant and Normal B Cells: Implications for Tumor Immunity and Autoimmunity
Current Pharmaceutical Design The Molecular Bases of the Self-Renewal and Differentiation of Leukemic Stem Cells
Current Cancer Therapy Reviews Stem Cells Therapies in Basic Science and Translational Medicine: Current Status and Treatment Monitoring Strategies
Current Pharmaceutical Biotechnology Bortezomib and Arsenious Acid Synergistically Inhibit HL-60 Cells Viability in vitro and in vivo
Current Signal Transduction Therapy Epidemiology and Prevention of Viral Infections in Patients with Hematologic Malignancies
Infectious Disorders - Drug Targets NBS1 Heterozygosity and Cancer Risk
Current Genomics Biosurfactants as a Novel Additive in Pharmaceutical Formulations: Current Trends and Future Implications
Current Drug Metabolism Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials
Current Cancer Drug Targets